Is Lamivudine oral in shortage right now?

No. FDA does not currently list Lamivudine oral in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.

Who makes Lamivudine oral?

2 companies have marketed Lamivudine oral in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.

What does Lamivudine oral cost?

The typical pharmacy pays about $0.2176 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.

Market view

lamivudine oral

3 marketed package NDCs · 2 active manufacturers

Most dispensed: LAMIVUDINE 10 mg/mL · Solution · #240 mL/bottle, plastic

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price is down 12% over the past year, to $0.2176 per mL.

Price range and competition

RSS: changes for this drug

Every company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.

Latest · Sep 2026 — typical price $0.2176 · middle half $0.2176–$0.2176 · full range $0.2176–$0.2176 · 1 products · 2 companies

middle half of companies’ pricestypical (median) pricewhat manufacturers charge wholesalers (WAMP)companies actively selling (bottom lane)Priced per mLⓘSource: CMS NADAC

ⓘ How this was built

Data sources

CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
CMS Federal Upper Limit files (weighted AMP)
FDA NDC Directory (openFDA) — maker roster

Method

Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Same drug class

Other molecules FDA puts in Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.

Common questions

Is Lamivudine oral in shortage right now?: No. FDA does not currently list Lamivudine oral in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
Who makes Lamivudine oral?: 2 companies have marketed Lamivudine oral in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
What does Lamivudine oral cost?: The typical pharmacy pays about $0.2176 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.

All marketed products

Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.